Cost saving analysis of reduced-dose versus standard-dose bevacizumab in recurrent glioblastoma

被引：0
|
作者：
Gleeson, Jack Patrick
Greene, John Patrick
Mullally, William J.
Brady, Claire
Goggin, Caitriona
Dennehy, Colum
Power, Derek Gerard
Hennessy, Bryan
Breathnach, Oscar S.
Bambury, Richard Martin
O'Reilly, Seamus
Grogan, William
Collins, Dearbhaile Catherine
Morris, Patrick G.
O'Mahony, Deirdre
机构：
[1] Cork Univ Hosp, Cork, Ireland
[2] Mercy Univ Hosp, Cork, Ireland
[3] Royal Coll Surgeons Ireland, Beaumont Hosp, Dublin, Ireland
[4] Beaumont Hosp, Dept Med Oncol, Dublin, Ireland
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Weill Cornell Med Coll, New York, NY USA
[7] Inst Canc Res, Sutton, Surrey, England
[8] Royal Marsden Hosp, Sutton, Surrey, England
[9] Beaumont Hosp, Dublin, Ireland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e18910
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18910
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The effect of off-label use of reduced-dose direct oral anticoagulants therapy in the treatment of pulmonary embolism comparable to standard-dose therapy
    Shinji Yamazoe
    Hajime Imai
    Yasuhiro Ogawa
    Naoaki Kano
    Yosuke Murase
    Keita Mamiya
    Tomoyo Ikeda
    Kei Hiramatsu
    Jun Torii
    Katsuhiro Kawaguchi
    Heart and Vessels, 2024, 39 (4) : 365 - 372
  • [42] Survival Benefit with Standard-Dose Decitabine Versus Standard-Dose Azacitidine in Patients with Lower-Risk Myelodysplastic Syndromes
    Lee, Byung-Hyun
    Kang, Ka-Won
    Jeon, Min Ji
    Yu, Eun Sang
    Kim, Dae Sik
    Choi, Hojoon
    Lee, Se Ryun
    Sung, Hwa Jung
    Park, Yong
    Choi, Chul Won
    Kim, Byung Soo
    BLOOD, 2018, 132
  • [43] RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (RGBM)
    Ahluwalia, Manmeet
    Peereboom, David
    Rauf, Yasmeen
    Lathia, Justin
    Alban, Tyler
    Schilero, Cathy
    Ciolfi, Marci
    LaForest-Roys, Corey
    Nayak, Lakshmi
    Lee, Eudocia
    Wen, Patrick
    Reardon, David
    NEURO-ONCOLOGY, 2020, 22 : 35 - 35
  • [44] Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
    Ahluwalia, Manmeet Singh
    Rauf, Yasmeen
    Li, Hong
    Wen, Patrick Y.
    Peereboom, David M.
    Reardon, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] Standard- vs reduced-dose DOAC for older adults: greater risk of bleeding with standard dose
    Reactions Weekly, 2023, 1984 (1) : 10 - 10
  • [46] High-dose versus standard-dose amoxicillin for acute otitis media
    Garrison, GD
    Sorum, PC
    Hioe, W
    Miller, MM
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (01) : 15 - 19
  • [47] COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB, FOTEMUSTINE AND EXTENDED-DOSE TEMOZOLOMIDE IN PATIENTS WITH RECURRENT GLIOBLASTOMA IN SPAIN
    Lopez, Garcia J. L.
    Barrios, Rodriguez J. M.
    Junoy, Puig J.
    Mena, Carrato A.
    VALUE IN HEALTH, 2014, 17 (07) : A638 - A638
  • [48] Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma
    Tomohiro Nishi
    Yasuo Hamamoto
    Etsuko Warita
    Junko Miyamoto
    Noriyuki Akutsu
    Yasuhiro Yamanaka
    Michitaka Nagase
    Hirofumi Fujii
    International Journal of Clinical Oncology, 2011, 16 : 488 - 493
  • [49] Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma
    Nishi, Tomohiro
    Hamamoto, Yasuo
    Warita, Etsuko
    Miyamoto, Junko
    Akutsu, Noriyuki
    Yamanaka, Yasuhiro
    Nagase, Michitaka
    Fujii, Hirofumi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2011, 16 (05) : 488 - 493
  • [50] Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma
    Gleeson, Jack Patrick
    Keane, Fergus
    Keegan, Niamh M.
    Mammadov, Emin
    Harrold, Emily
    Alhusaini, Abdullah
    Harte, Jeffrey
    Eakin-Love, Austin
    O'Halloran, Philip J.
    MacNally, Stephen
    Hennessy, Bryan T.
    Breathnach, Oscar S.
    Grogan, Liam
    Morris, Patrick G.
    CANCER MEDICINE, 2020, 9 (02): : 469 - 475
12345